araag2/HINT huggingface dataset:
Clinical trial NCT00266877 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung, lung neoplasms
ICD codes: D02.20, D02.21, D02.22, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: hki-272
SMILES: CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologic diagnosis of NSCLC and current stage IIIB (with pleural effusion) or IV,
             not curable with conventional therapy. For Arm C, less than or equal to 20 pack-years
             smoking history and current non smoker. A pack year = number of packs of cigarettes
             smoked per day x years smoked.

          -  Progression following at least 12 weeks of treatment with Tarceva or Iressa. (Arms A
             and B only)

          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2 (not
             declining within past 2 weeks).

          -  Tumor sample available and adequate for analysis.

          -  At least one measurable target lesion.

          -  Adequate cardiac, kidney, and liver function

          -  Adequate blood counts

        Exclusion Criteria:

          -  More than 3 prior cytotoxic chemotherapy treatments for relapsed or metastatic
             disease.

          -  Significant cardiac disease or dysfunction.

          -  Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2.

          -  Active central nervous system metastases, as indicated by clinical symptoms and/or
             progressive growth.

          -  Use of Tarceva or Iressa within 14 days of treatment day 1 (Arms A and B only).

          -  Major surgery, chemotherapy, radiotherapy, investigational drugs, or other cancer
             therapy within 3 weeks of treatment day 1.

          -  Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major
             symptom.

          -  Inability or unwillingness to swallow HKI-272 capsules.

          -  Pregnant or breastfeeding women.
Clinical trial NCT00312052 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: e5555, placebo
SMILES: CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        INCLUSION CRITERIA:

          1. Males or Females, 45 - 80 years of age

          2. Confirmed coronary artery disease defined as one of the following:

               -  Post-acute coronary syndrome or myocardial infarction or

               -  Post percutaneous coronary intervention or coronary artery bypass graft or
                  oAngina pectoris with documented (electrocardiogram or imaging study) ischemia or

               -  Angiographically documented lesion occluding ≥70% of a coronary vessel

             And at high risk as defined as one or more of the following:

               -  Elevated hsCRP (high-sensitivity C-reactive protein)

               -  Diabetes mellitus

               -  History of carotid artery disease and/or peripheral artery disease

               -  Thrombo-embolic transient ischemic attack or stroke >1 year prior to screening

          3. All subjects must be receiving low dose aspirin and/or clopidogrel and/or ticlopidine.

        EXCLUSION CRITERIA

          1. History of acquired or congenital bleeding disorder, coagulopathy or platelet
             disorder, or history of pathological bleeding within the last 6 months

          2. History of intracranial bleeding, history of hemorrhagic retinopathy or known
             structural cerebral vascular lesion

          3. Clinically significant hematological, hepatic or renal abnormalities

          4. Patients with some specific ST-segment changes, severe congestive heart failure or
             uncontrolled cardiac arrhythmias at baseline

          5. Recent significant (as determined by the investigator) cardiovascular events
Clinical trial NCT01472991 (phase 2, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: tc-5619-238 5mg, tc-5619-238 25mg, placebo
SMILES: [H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2, [H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of Inattentive predominant ADHD per DSM-IV TR) criteria at Screening

          2. Score ≥ 2 on at least 6 of 9 items in the inattentive subscale of the CAARS-INV at
             Baseline (Day 1)

          3. Score of < 2 on at least 4 of 9 items in the hyperactive/impulsivity subscale of the
             CAARS-INV at Baseline (Day 1)

          4. Score ≥ 4 (at least moderate) on the CGI-S

          5. Tobacco non-users as indicated by lack of tobacco use within the last 6 months prior
             to Screening, and by negative urinary cotinine level of < 50 ng/mL after
             quantification

        Exclusion Criteria:

          1. Current DSM-IV Axis I psychiatric disorder other than ADHD;

          2. Use of tobacco cessation agents within 4 weeks prior to Screening

          3. Known or suspected drug abuse within the last 6 months prior to Screening

          4. Urine drug screen positive for illegal or non-prescribed drugs at Screening

          5. Patients at imminent risk of suicide or of danger to themselves or others as judged by
             the investigator

          6. Use of drugs affecting cognitive function within 4 weeks prior to Day 1. This includes
             use of any concomitant medications for treatment of ADHD.

          7. History of significant other major or unstable neurological, metabolic, hepatic,
             renal, hematological, pulmonary, cardiovascular (CV), gastrointestinal (GI), or
             urological disorder; or diagnosis of major depressive disorder

          8. Myocardial infarction within past year

          9. Seizure disorder within past year

         10. Type 1 diabetes mellitus (DM); type 2 DM that requires medication (diet-controlled
             allowed)

         11. HbA1C > 7.4 at Screening

         12. BMI < 15 or > 35; male weight < 100 lbs; female weight < 80 lbs.

         13. Current tuberculosis (TB) or known systemic infection [Hepatitis B Virus (HBV),
             Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)]

         14. Women of child-bearing potential and male participants unwilling or unable to use
             accepted methods of birth control

         15. Participation in another Central Nervous System (CNS)-related clinical trial in the
             last 3 months and any other clinical trial in last 30 days prior to Screening, or
             participation in a previous TC-5619 clinical trial
Clinical trial NCT01114581 (phase 2, status: completed)
Conditions: acute respiratory infection
ICD codes: J06.9, J22, J47.0, J44.0
Drugs: mucinex, placebo
SMILES: COC1=CC=CC=C1OCC(O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Symptoms of cough, thickened mucus and chest congestion

          -  Able to produce sputum

          -  Non Smoker

        Exclusion Criteria:

          -  Pregnant

          -  Smokers

          -  Fever above 101°F

          -  Any chronic illness
Clinical trial NCT00647296 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: kns-760704, kns-760704, kns-760704, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with diagnosis of familial or sporadic ALS, defined as meeting the possible,
             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS
             according to the World Federation of Neurology El Escorial criteria

          -  Patients with ALS symptom onset < 24 months from randomization

          -  Patients with upright VC > 65% of predicted for age, height, and gender

        Exclusion Criteria:

          -  Patients in whom causes of neuromuscular weakness other than ALS have not been
             excluded

          -  Patients without clinical evidence of upper motor neuron dysfunction

          -  Patients with clinically suspected ALS according to the World Federation of Neurology
             El Escorial criteria

          -  Patients with prior exposure to KNS-760704 or the R(+) enantiomer of pramipexole
             (i.e., R(+)-pramipexole)

          -  Patients taking other investigational agents (including lithium) within 30 days of
             randomization or during the study
Clinical trial NCT01425801 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: las100977 0.313 μg, las100977 0.625 μg, las100977 1.25 μg, las100977 2.5 μg, salbutamol 400 μg, salbutamol placebo, las100977 placebo
SMILES: O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Adult male and female patients aged 18-70 years (both included).

          2. Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for
             at least 6 months prior to screening.

          3. Screening FEV1 value of 60% < FEV1 ≤ 85% of the predicted normal value.

          4. FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline
             value after inhalation of 400µg (four inhalations) of salbutamol.

          5. Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1
             measured at screening prior to salbutamol inhalation.

          6. Patients on a stable dose and regimen

        Exclusion Criteria:

          1. Current smokers, former smokers within the last 6 months, or ex-smokers with a history
             of more than 10 pack-years.

          2. Patients diagnosed with COPD.

          3. Recent Respiratory tract infections within 6 weeks before Screening Visit.

          4. Intubation (ever) or hospitalization for longer than 24 hours for the management of an
             asthma exacerbation within the preceding 6 weeks of the screening visit.

          5. Clinically significant respiratory conditions.

          6. Clinically significant cardiovascular conditions.

          7. Patients unable to properly use a dry powder or pMDI inhaler device or unable to
             perform acceptable spirometry.

          8. Clinically relevant abnormalities laboratory, ECG parameters or physical examination
             results at the screening evaluation that in the investigator's opinion, preclude study
             participation.

          9. Patients who intend to use any concomitant medication not permitted by this protocol
             or who have not undergone the required washout period for a particular prohibited
             medication.
Clinical trial NCT00291733 (phase 2, status: unknown status)
Conditions: levodopa induced dyskinesia
ICD codes: K22.4, G24.01
Drugs: levetiracetam, placebo
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Diagnosis of PD will be according to the criteria of United Kingdom Parkinson's Disease
        Society Brain Bank.

        Other inclusion criteria:

          -  Patients between ages 30 and 80

          -  Hoehn and Yahr stage of PD over IIb

          -  Levodopa-induced dyskinesias (LID) despite optimization of antiparkinsonian medication

          -  LID severity 2 on item 32 and duration 2 on item 33 of the Unified Parkinson's Disease
             Rating Scale (UPDRS) part IV

          -  Patient is willing to adhere to protocol requirements as evidence by written informed
             consent

        Exclusion Criteria:

          -  Patient has a history of any medical condition or clinically significant laboratory
             abnormalities that can subject them to unwarranted risk.

          -  Female patient is pregnant or breastfeeding or has not been using or was not
             continuing to use an adequate contraceptive method for the last 30 days, or is not at
             least one year post-menopausal.

          -  Patient with ablative surgeries or DBS implantation electrodes for diseases of the
             basal ganglia.

          -  Patient has a low Mini-mental Examination MMSE score <25 or has a history of bipolar
             psychosis or schizophrenia.

          -  Patient is unwilling to sign an informed consent or to comply with protocol
             requirements.

          -  Patient is taking or has taken in the past month amantadine.
Clinical trial NCT00638833 (phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: memantine, placebo
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    unexpected side-effects: reversible and mild to moderate neurological impairment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with MS (McDonald 2002), both sex, age between 18 to 60 years old, all MS
             subtypes (RR, SP, PP, PR), stable.

          -  Patients with severe cognitive impairment defined as performing 1.5 SD below control
             group (matched by age and education) in 2 o more subtests based in our previous study
             (Sepulcre 2006):

        Exclusion Criteria:

          -  Psychiatric diseases (Cummings) depression (Hamilton >8), drug or alcohol abuse,
             benzodiazepine therapy or other medical diseases.
Clinical trial NCT00320320 (phase 2, status: terminated)
Conditions: colorectal neoplasms, metastases
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of colon and rectum

          -  No prior chemotherapy or only adjuvant chemotherapy and/or radiotherapy

          -  Advanced, metastatic or recurrent not amenable to curative local therapy

          -  Measurable lesion(s)

          -  ECOG performance status 0 to 2

          -  Normal marrow, hepatic and renal function

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Active infection and/or severe comorbidity

          -  Known history of anaphylaxis of any origin
Clinical trial NCT00686998 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: azd2624, olanzapine, placebo
SMILES: CC[C@H](NC(=O)C1=C(NS(C)(=O)=O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females of non-childbearing potential

          -  Diagnosis of Schizophrenia

        Exclusion Criteria:

          -  Clinically relevant disease and /or abnormalities.

          -  Alcohol or substance abuse not in remission

          -  Enrollment in another investigational study within 30 days
Clinical trial NCT00626444 (phase 2, status: terminated)
Conditions: non-hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: intravenous vitamin c
SMILES: [H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age greater than 18 years old

          -  Aggressive or very aggressive NHL

          -  Failed one or more therapies

          -  Patients must not have progressed within 60 days of last therapy

          -  Not received allogeneic stem cell transplant

          -  No reasonable standard therapeutic options available

          -  Glucose 6 phosphate dehydrogenase status normal

          -  ECOG performance status 0-2

          -  Normal creatinine and transaminase

          -  Women of child-bearing potential confirm negative pregnancy test

        Exclusion Criteria:

          -  Significant co-morbid disorders

          -  Significant psychiatric symptoms

          -  Smoking

          -  Excessive alcohol or drug use

          -  Enrollment in other experimental therapy

          -  Active infection

          -  Patients experiencing ongoing response to recent treatments

          -  Patients who have received chemotherapy within 30 days or biological therapy within 6
             weeks
Clinical trial NCT01902862 (phase 2, status: terminated)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bortezomib, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    recruitment too slow
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with histologically confirmed relapsed or refractory follicular Stage III
             or IV, Grade 1 and 2, cluster of differentiation 20 plus (CD20+) lymphoma (WHO - World
             Health Organization) that requires therapy

          -  Participants in whom treatment with rituximab is planned after greater than or equal
             to 2 cytostatic (inhibition of cell growth) previous therapies

          -  Women must be either postmenopausal or sterilized; negative pregnancy test at
             Screening

          -  Participants with total bilirubin below 1.5-fold upper limit of normal (ULN) and
             creatinine below 2-fold ULN

          -  Participants with Karnofsky Status greater than or equal to 60 percent

        Exclusion Criteria:

          -  Participants with previous treatment with bortezomib within 6 months before enrollment
             or previous treatment with a combination of rituximab and bortezomib

          -  Participants with previous known allergic reaction to bortezomib, boron or mannitol

          -  Participants with life-expectancy of less than 3 months

          -  Participants with malignant neoplasm (cancerous - new growth that is not normal;
             tumor) (except basalioma) within previous 5 years

          -  Participants with peripheral (not central) neuropathy (a disturbance in the function
             of the brain or spinal cord that may affect the nerves and muscles of the body) common
             terminology criteria for adverse events (CTCAE) grade greater than or equal to 2
Clinical trial NCT00528333 (phase 2, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: lintuzumab (sgn-33), low dose cytarabine, placebo
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Untreated AML that occurred de novo, after prior exposure to chemotherapy for a
             separate malignancy, or evolved from an antecedent hematologic disorder.

          -  After being informed of the potential benefits and risks of available treatment
             options, patients must have declined intensive chemotherapy for AML.

          -  At least 20% blasts in blood or marrow.

          -  Must have a minimum of 50% leukemic blasts that express CD33.

          -  ECOG performance status score of 0 to 2.

          -  WBC less than 30,000/µL

        Exclusion Criteria:

          -  No known diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia.

          -  No other active systemic malignancies treated with chemotherapy within the last 12
             months.

          -  Must not have received previous chemotherapy (except hydroxyurea) for AML.

          -  Must not have significantly abnormal kidney or liver disease.

          -  Must not have known human immunodeficiency virus (HIV).
Clinical trial NCT00191308 (phase 2, status: completed)
Conditions: non-small cell lung cancer, carcinoma
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: pemetrexed, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  pathologic documentation of non-small cell lung cancer (NSCLC)

          -  tumor must be accessible by bronchoscopy for tumor tissue sample collection

          -  patients must have lung cancer with clinical stage IB, II, IIIA

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  patients must not have received prior systemic chemotherapy or radiation therapy for
             NSCLC (prior resection of lung is allowed provided at least 5 years have elapsed
             between prior surgery and enrolment)

        Exclusion Criteria:

          -  bronchoalveolar carcinoma or stage IIIA tumor involving the superior sulcus (Pancoast
             tumors)

          -  pregnant or breast feeding patients

          -  patients who have received treatment within the last 30 days with a drug that has not
             received regulatory approval for any indication at the time of study entry

          -  patients with history or presence of other malignancy except in situ carcinoma of the
             skin or prior malignancy treated more than 5 years before without recurrence
             (excluding melanoma, breast cancer and hypernephroma)

          -  unwillingness to take folic acid or vitamin B12 supplementation
Clinical trial NCT01291823 (phase 2, status: unknown status)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented diagnosis of esophageal Cancer

          -  Disease must be encompassed in a radiotherapy field.Patients with celiac, perigastric,
             mediastinal or supraclavicular adenopathy are eligible

          -  age:70-85 years

          -  Written informed consent.

          -  Performance status of 0 to 2

          -  Neutrophil count >1.5 x 10 to the 9th power/L and platelets > 100 x 10 to the 9th
             power/L.

          -  Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN)
             Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5
             times ULN (or less than or equal to 5 times ULN in case of known liver involvement

          -  Renal: Serum Creatinine less than or equal to 1.5 times upper limit of normal (ULN)

        Exclusion Criteria:

          -  Evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi.

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity,
             or cervix are all permissible).

          -  Prior systemic chemotherapy or radiation therapy for esophageal cancer